Advertisement

Neurourology pp 231-259 | Cite as

Drug Treatment

  • Karl-Erik AnderssonEmail author
  • Helmut Madersbacher
  • Waleed Altaweel
  • Pawan Vasudeva
  • Yasuhiko Igawa
Chapter

Abstract

Neurogenic lower urinary tract dysfunction (NLUTD) is a heterogeneous combination of symptoms and urodynamic findings that are the result of neurological injury to the bladder (Fig. 27.1) [1–4]. The patterns of bladder storage and voiding disturbances depend on the lesion of neurologic lesion (Fig. 27.2). Patients often have incontinence, urgency, frequency and/or impaired bladder emptying. Urodynamically, there is often poor bladder wall compliance, neurogenic detrusor overactivity (NDO) and/or detrusor sphincter dyssynergia (DSD) which may result in morphological changes in the bladder wall, such as trabeculations and diverticulae. NLUTD can be found in 85–90% of patients with spinal cord injury (SCI), with urinary incontinence occurring in more than 50% NLUTD also occurs in 50–80% of patients with multiple sclerosis (MS), in 27–64% of patients with Parkinson’s disease, and in over 95% of patients with spina bifida [3]. It also occurs frequently with many other neurological conditions such as after stroke, transverse myelitis, and autonomic disorders [1–4].

References

  1. 1.
    Drake MJ, Apostolidis A, Cocci A, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourol Urodyn. 2016;35:657–65.Google Scholar
  2. 2.
    Sturm RM, Cheng EY. The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep. 2016;11:225–33.Google Scholar
  3. 3.
    Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263:2555–64.Google Scholar
  4. 4.
    Wyndaele JJ. The management of neurogenic lower urinary tract dysfunction after spinal cord injury. Nat Rev Urol. 2016;13:705–14.Google Scholar
  5. 5.
    Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.Google Scholar
  6. 6.
    Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.Google Scholar
  7. 7.
    Cameron AP, Wallner LP, Tate DG, et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184:213–7.Google Scholar
  8. 8.
    Borau A, Adot JM, Allué M, et al. A systematic review of the diagnosis and treatment of patients with neurogenic hyperactivity of the detrusor muscle. Actas Urol Esp. 2017;42:5–16.Google Scholar
  9. 9.
    Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.Google Scholar
  10. 10.
    Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319–44.Google Scholar
  11. 11.
    Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Phys. 1998;275:1654–60.Google Scholar
  12. 12.
    Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Phys. 2004;286:874–80.Google Scholar
  13. 13.
    Schneider T, Hein P, Michel-Reher M, et al. Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedeberg's Arch Pharmacol. 2005a;372:71–8.Google Scholar
  14. 14.
    Schneider T, Hein P, Bai J, et al. A role for muscarinic receptors or rho-kinase in hypertension associated rat bladder dysfunction? J Urol. 2005b;173:2178–81.Google Scholar
  15. 15.
    Yoshida M, Homma Y, Inadome A, et al. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol. 2001;3:99–109.Google Scholar
  16. 16.
    Yoshida M, Masunaga K, Satoji Y, et al. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci. 2008;106:193–8.Google Scholar
  17. 17.
    Rapp DE, Lyon MB, Bales GT, et al. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol. 2005;48:303–8.Google Scholar
  18. 18.
    Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184:2578–85.Google Scholar
  19. 19.
    Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al, editors. 6th International Consultation on Incontinence, Tokyo, September 2016, The International Continence Society (ICS) and the International Consultation on Urological Diseases (ICUD). 2017.Google Scholar
  20. 20.
    Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62:816–30.Google Scholar
  21. 21.
    Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.Google Scholar
  22. 22.
    Naja M, Zmudka J, Hannat S, et al. In geriatric patients, delirium symptoms are related to the anticholinergic burden. Geriatr Gerontol Int. 2016;16:424–31.Google Scholar
  23. 23.
    Moga DC, Abner EL, Wu Q, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y). 2017;3:139–48.Google Scholar
  24. 24.
    Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health. 2015;19:217–23.Google Scholar
  25. 25.
    Swami S, Cohen RA, Kairalla JA, et al. Anticholinergic drug use and risk to cognitive performance in older adults with questionable cognitive impairment: a cross-sectional analysis. Drugs Aging. 2016;33:809–18.Google Scholar
  26. 26.
    Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51:432–41.Google Scholar
  27. 27.
    Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn. 2006;25:441–5.Google Scholar
  28. 28.
    Amend B, Hennenlotter J, Schäfer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008;53:1021–8.Google Scholar
  29. 29.
    Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157:1093–7.Google Scholar
  30. 30.
    Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140:47–50.Google Scholar
  31. 31.
    Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12:12–9.Google Scholar
  32. 32.
    Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J. 2013;24:595–604.Google Scholar
  33. 33.
    Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6:243–62.Google Scholar
  34. 34.
    Thüroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16:S48–61.Google Scholar
  35. 35.
    Hussain RM, Hartigan-Go K, Thomas SHL, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1994;37:485.Google Scholar
  36. 36.
    Arisco AM, Brantly EK, Kraus SR. Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug Des Devel Ther. 2009;3:151–61.Google Scholar
  37. 37.
    Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696.Google Scholar
  38. 38.
    Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended- release: a review of its use in the management of overactive bladder. Drugs. 2004;64:885.Google Scholar
  39. 39.
    Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62:1792–800.Google Scholar
  40. 40.
    Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12:351–7.Google Scholar
  41. 41.
    Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998;55:813–20.Google Scholar
  42. 42.
    Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18:277–304.Google Scholar
  43. 43.
    Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008;9:1249–55.Google Scholar
  44. 44.
    Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414–21.Google Scholar
  45. 45.
    Watanabe M, Yamanishi T, Honda M, et al. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. Int J Urol. 2010;17:931–6.Google Scholar
  46. 46.
    Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007;81:377–85.Google Scholar
  47. 47.
    Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000;38:223.Google Scholar
  48. 48.
    Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44:701.Google Scholar
  49. 49.
    Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65:238–42.Google Scholar
  50. 50.
    Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294–300.Google Scholar
  51. 51.
    Chancellor MB, Staskin DR, Kay GG, et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29:259–73.Google Scholar
  52. 52.
    Stöhrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo controlled double-blind trial. Urol Int. 1991;47:138.Google Scholar
  53. 53.
    Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452.Google Scholar
  54. 54.
    Allousi S, Laval K-U, Eckert R. Trospium chloride (Spasmolyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J Clin Res. 1998;1:439.Google Scholar
  55. 55.
    Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392.Google Scholar
  56. 56.
    Zinner N, Gittelman M, Harris R, et al. Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004a;171:2311.Google Scholar
  57. 57.
    Bödeker RH, Madersbacher H, Neumeister C, et al. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010;10:15.Google Scholar
  58. 58.
    Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride20 mg in healthy adults. J Clin Pharmacol. 2010;50:143–50.Google Scholar
  59. 59.
    Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63:1715–23.Google Scholar
  60. 60.
    Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung. 1992;42:815–7.Google Scholar
  61. 61.
    Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedeberg's Arch Pharmacol. 2006;374:87–97.Google Scholar
  62. 62.
    Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19:324–35.Google Scholar
  63. 63.
    McKeage K. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig. 2013;33:71–91.Google Scholar
  64. 64.
    Stöhrer M, Mürtz G, Kramer G, et al. Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity. Spinal Cord. 2013;51:419–23.Google Scholar
  65. 65.
    Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc. 2009;57:1515–7.Google Scholar
  66. 66.
    Oelke M, Murgas S, Schneider T, et al. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a non-interventional study to assess real life data. In 43rd Annual Meeting of the ICS, Barcelona, 2013.Google Scholar
  67. 67.
    Schulte-Baukloh H, Mürtz G, Henne T, et al. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int. 2006;97:355–8.Google Scholar
  68. 68.
    Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Urology. 2003;61:37–49.Google Scholar
  69. 69.
    Stewart W, Herzog R, Wein A. at al. The prevalence and impact of overactive bladder in the US: results from NOBLE program. Neurourol Urodyn. 2001;20:406–8.Google Scholar
  70. 70.
    Milsom I, Abrams P, Cardozo L, Robert RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int. 2001;87:760–6.Google Scholar
  71. 71.
    VESIcare [package insert]. Deerfield, II1: Astellas Pharma US, Inc; 2004.Google Scholar
  72. 72.
    Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48:281–302.Google Scholar
  73. 73.
    Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023–33.Google Scholar
  74. 74.
    Smulders RA, Smith NN, Krauwinkel WJ, et al. Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients with Renal Insufficiency. J Pharmacol Sci. 2007;103:67–74.Google Scholar
  75. 75.
    Kuipers M, Smulders R, Krauwinkel W, et al. Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects with Hepatic Impairment. J Pharmacol Sci. 2006;102:405–12.Google Scholar
  76. 76.
    Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631.Google Scholar
  77. 77.
    Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology. 2002;60:719–25.Google Scholar
  78. 78.
    Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediates contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2002;21:1–6.Google Scholar
  79. 79.
    Golan DE, Tashjian AH, Armstrong EJ, et al. Principles of Pharmacology. The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins: Baltimore, Md; 2005.Google Scholar
  80. 80.
    Caulfield MP, Birdsall NJM. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279–90.Google Scholar
  81. 81.
    Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273:959–66.Google Scholar
  82. 82.
    Nakamura T, Kimura J, Yamaguchi O. Muscarinic M2 receptors inhibit Ca2+−activated K+ channels in rat bladder smooth muscle. Int J Urol. 2002;9:689–96.Google Scholar
  83. 83.
    Pontari MA, Braverman AS, Sr RM, et al. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol. 2004;286:874–80.Google Scholar
  84. 84.
    Swart PJ, Krauwinkel WJ, Smulders RA, et al. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2006;99:33–6.Google Scholar
  85. 85.
    Taekema-Roelvink ME, Swart PJ, Kuipers ME, et al. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther. 2005;27:1403–10.Google Scholar
  86. 86.
    Michel MC, Minematsu T, Hashimoto T, et al. In vitro studies on the potential of solifenacin for drug-drug interaction: plasma protein and MDR 1 transport. Br J Clin Pharmacol. 2015;59:647.Google Scholar
  87. 87.
    Govier FE, Smith N, Uchida T. Efficacy and safety of 10 mg solifenacin succinate in patients with overactive bladder syndrome: results from a randomized, double-blind, placebo-controlled phase III pivotal trial. Clin Med Insights Urol. 2010;4:11–20.Google Scholar
  88. 88.
    Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100:579–87.Google Scholar
  89. 89.
    Chapple C, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–10.Google Scholar
  90. 90.
    Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.Google Scholar
  91. 91.
    Cardozo L, Lisec M, Millard R. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–24.Google Scholar
  92. 92.
    Kelleher C, Cardozo L, Chapple C. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005;95:81–5.Google Scholar
  93. 93.
    Cardozo L, Amarenco G, Pushkar G, et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013;111:804–10.Google Scholar
  94. 94.
    Steers WD. Darifenacin: Pharmacology and clinical usage. Urol Clin North Am. 2006;33:475–82.Google Scholar
  95. 95.
    Smith PP, Lai HH, Appell RA. Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. Therapy. 2006;3:723–32.Google Scholar
  96. 96.
    Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45:325–50.Google Scholar
  97. 97.
    Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology. 2006;68:250.Google Scholar
  98. 98.
    Bycroft J, Leaker B, Wood S, et al. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Neurourol Urodyn. 2003;22:A190.Google Scholar
  99. 99.
    Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98:1025–32.Google Scholar
  100. 100.
    Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72:235–46.Google Scholar
  101. 101.
    Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96:1055–62.Google Scholar
  102. 102.
    Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agent’s darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.Google Scholar
  103. 103.
    Wesnes K, Lipton R, Kolodner K, et al. Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur Urol. 2004;3:131.Google Scholar
  104. 104.
    Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants & gt; or = 50 years. J Cardiovascular Pharmacol Ther. 2008;13:241–51.Google Scholar
  105. 105.
    Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140.Google Scholar
  106. 106.
    Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23:263.Google Scholar
  107. 107.
    Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51:907.Google Scholar
  108. 108.
    Sahai A, Mallina R, Dowson C, et al. Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract. 2008;62:167.Google Scholar
  109. 109.
    Staskin DR, Salvatore S. Oxybutynin topical and transdermal formulations: an update. Drugs Today (Barc). 2010;46:417–25.Google Scholar
  110. 110.
    Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermaloxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011;107:70–6.Google Scholar
  111. 111.
    Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. J Pediatr Urol. 2014;10:753–7.Google Scholar
  112. 112.
    Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181:1764–72.Google Scholar
  113. 113.
    Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10:3103–11.Google Scholar
  114. 114.
    Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011;31:559–71.Google Scholar
  115. 115.
    Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012;206:168.e1–6.Google Scholar
  116. 116.
    Fader M, Glickman S, Haggar V, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol. 2007;177:208–13.Google Scholar
  117. 117.
    Humblet M, Verpoorten C, Christiaens MH, et al. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn. 2015;34:336–42.Google Scholar
  118. 118.
    Fröhlich G, Burmeister S, Wiedemann A, et al. Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test. Arzneimittelforschung. 1998;48:486.Google Scholar
  119. 119.
    Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn. 1999;18:447–53.Google Scholar
  120. 120.
    Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292–301.Google Scholar
  121. 121.
    Giuliano F, Ückert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63:506–16.Google Scholar
  122. 122.
    Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11:231–41.Google Scholar
  123. 123.
    Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol. 2010;59:272–9.Google Scholar
  124. 124.
    Morelli A, Filippi S, Sandner P, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009b;6:1594–608.Google Scholar
  125. 125.
    Nomiya M, Burmeister DM, Sawada N, et al. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2013;189:754–61.Google Scholar
  126. 126.
    McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401–7.Google Scholar
  127. 127.
    Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228–34.Google Scholar
  128. 128.
    Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917–25.Google Scholar
  129. 129.
    Gacci M, Andersson KE, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–33.Google Scholar
  130. 130.
    Cameron AP, Clemens JQ, Latini JM, et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182:1062–7.Google Scholar
  131. 131.
    Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:1624–33.Google Scholar
  132. 132.
    Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2013;189:S135–40.Google Scholar
  133. 133.
    Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993;45:253–308.Google Scholar
  134. 134.
    Nergårdh A, Boréus LO, Naglo AS. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol. 1977;40:14–21.Google Scholar
  135. 135.
    Larsen JJ. Alpha and beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man. Br J Pharmacol. 1979;65:215–22.Google Scholar
  136. 136.
    Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989;245:1118–21.Google Scholar
  137. 137.
    Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedeberg's Arch Pharmacol. 2013;386:177–83.Google Scholar
  138. 138.
    Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126:819–25.Google Scholar
  139. 139.
    Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999;288:1367–73.Google Scholar
  140. 140.
    Fujimura K, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;161:680–5.Google Scholar
  141. 141.
    Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedeberg's Arch Pharmacol. 2008;377:473–81.Google Scholar
  142. 142.
    Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170:649–53.Google Scholar
  143. 143.
    Igawa Y, Yamazaki Y, Takeda H, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol. 2001;165:240–4.Google Scholar
  144. 144.
    Igawa Y, Aizawa N, Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51:811–8.Google Scholar
  145. 145.
    Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147:S88–119.Google Scholar
  146. 146.
    Hudman D, Elliott RA, Norman RI. K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle. Eur J Pharmacol. 2000;397:169–76.Google Scholar
  147. 147.
    Frazier EP, Mathy MJ, Peters SL, et al. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther. 2005;313:260–6.Google Scholar
  148. 148.
    Frazier EP, Peters SLM, Braverman AS, et al. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol. 2008;377:449–62.Google Scholar
  149. 149.
    Uchida H, Shishido K, Nomiya M, et al. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors. Eur J Pharmacol. 2005;518:195–202.Google Scholar
  150. 150.
    Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98:1310–4.Google Scholar
  151. 151.
    Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642–7.Google Scholar
  152. 152.
    Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165–73.Google Scholar
  153. 153.
    Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110:E132–42.Google Scholar
  154. 154.
    Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedeberg's Arch Pharmacol. 2013;386:247–53.Google Scholar
  155. 155.
    Michel MC, Igawa Y. Therapeutic targets for overactive bladder other than smooth muscle. Expert Opin Ther Targets. 2015;19:687–705.Google Scholar
  156. 156.
    Rouget C, Rekik M, Camparo P, et al. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res. 2014;80:14–20.Google Scholar
  157. 157.
    D’Agostino G, Condino AM, Calvi P. Involvement of β-adrenoceptors in the inhibitory control 3 of cholinergic activity in human bladder: direct evidence 3 by [H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–22.Google Scholar
  158. 158.
    Birder LA, Nealen ML, Kiss S, et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci. 2002;22:8063–70.Google Scholar
  159. 159.
    Murakami S, Chapple CR, Akino H, et al. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int. 2007;99:669–73.Google Scholar
  160. 160.
    Masunaga K, Chapple CR, McKay NG, et al. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol Urodyn. 2010;29:1320–5.Google Scholar
  161. 161.
    Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol. 2001;166:1142–7.Google Scholar
  162. 162.
    Takeda H, Yamazaki Y, Igawa Y, et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002;21:558–65.Google Scholar
  163. 163.
    Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002;168:1247–52.Google Scholar
  164. 164.
    Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323:202–9.Google Scholar
  165. 165.
    Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50:838–50.Google Scholar
  166. 166.
    Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a β(3)-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34:2144–60.Google Scholar
  167. 167.
    Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012a;40:815–24.Google Scholar
  168. 168.
    Füllhase C, Soler R, Westerling-Andersson K, et al. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011;30:1382–7.Google Scholar
  169. 169.
    Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. 2012b;42:957–67.Google Scholar
  170. 170.
    Takusagawa S, Miyashita A, Iwatsubo T, et al. In vitro inhibition and induction of human cytochrome P450 enzymes bymirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012c;42:1187–96.Google Scholar
  171. 171.
    Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.Google Scholar
  172. 172.
    Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46:275–84.Google Scholar
  173. 173.
    Rossanese M, Novara G, Challacombe B, et al. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU Int. 2015;115:32–40.Google Scholar
  174. 174.
    Suarez O, Osborn D, Kaufman M, et al. Mirabegron for male lower urinary tract symptoms. Curr Urol Rep. 2013;14:580–4.Google Scholar
  175. 175.
    Otsuki H, Kosaka T, Nakamura K, et al. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53–60.Google Scholar
  176. 176.
    Abrams P, Kelleher C, Staskin D. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–88.Google Scholar
  177. 177.
    Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinalcord injury. Spinal Cord. 2016;54:78–82.Google Scholar
  178. 178.
    Wada N, Okazaki S, Kobayashi S, et al. Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo. 2015;61:7–11.Google Scholar
  179. 179.
    Kamei J, Furuta A, Akiyama Y, et al. Video-urodynamic effects of mirabegron, a β3-adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 2015;22:956–61.Google Scholar
  180. 180.
    Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24:1299–306.Google Scholar
  181. 181.
    Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016;17:1317–25.Google Scholar
  182. 182.
    Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62:834–40.Google Scholar
  183. 183.
    Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–23.Google Scholar
  184. 184.
    Di Salvo J, Nagabukuro H, Wickham LA, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360:346–55.Google Scholar
  185. 185.
    Abrams P, Amarenco G, Bakke A, et al. European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170:1242–51.Google Scholar
  186. 186.
    Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5:51–62.Google Scholar
  187. 187.
    Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4:368–78.Google Scholar
  188. 188.
    Moon KH, Park CH, Jung HC, et al. A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. Low Urin Tract Symptoms. 2015;7:27–31.Google Scholar
  189. 189.
    Swierzewski SJ 3rd, Gormley EA, Belville WD, et al. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol. 1994;151:951–4.Google Scholar
  190. 190.
    Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol. 1996;156:1125–30.Google Scholar
  191. 191.
    O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153:1114–6.Google Scholar
  192. 192.
    Kakizaki H, Ameda K, Kobayashi S, et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10:576–81.Google Scholar
  193. 193.
    Krum H, Louis WJ, Brown DJ, et al. A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res. 1992;2:83–8.Google Scholar
  194. 194.
    Chancellor MB, Erhard MJ, Hirsch IH, et al. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol. 1994;151:111–3.Google Scholar
  195. 195.
    Phillips AA, Elliott SL, Zheng MM, et al. Selective alpha adrenergic antagonist reduces severity of transient hypertension during sexual stimulation after spinal cord injury. J Neurotrauma. 2015;15(32):392–6.Google Scholar
  196. 196.
    Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62:1547–59.Google Scholar
  197. 197.
    Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13:1187–97.Google Scholar
  198. 198.
    de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52.Google Scholar
  199. 199.
    Taylor MC, Bates CP. A double-blind crossover trial of baclofen--a new treatment for the unstable bladder syndrome. Br J Urol. 1979;51:504.Google Scholar
  200. 200.
    Ochs GA. Intrathecal baclofen. Baillieres Clin Neurol. 1993;2:73–86.Google Scholar
  201. 201.
    Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn. 1993;12:163.Google Scholar
  202. 202.
    Szollar S, North J, Chung J. Antidiuretic hormone levels and polyuria in spinal cord injury. A preliminary report. Paraplegia. 1995;33:94–7.Google Scholar
  203. 203.
    Zahariou A, Karagiannis G, Papaioannou P, et al. The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura Medicophys. 2007;43:333–8.Google Scholar
  204. 204.
    Horowitz M, Combs AJ, Gerdes D. Desmopressin for nocturnal incontinence in the spina bifida population. J Urol. 1997;158:2267–8.Google Scholar
  205. 205.
    Del Gado R, Aceto G, Del Gaizo D, et al. Desmopressin for the treatment of nocturnal bedwetting in patients with neural tube closure defects. J Urol. 2004;171:1656–8.Google Scholar
  206. 206.
    Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc. 1994;17:165–7.Google Scholar
  207. 207.
    Bosma R, Wynia K, Havlíková E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112:1–5.Google Scholar
  208. 208.
    Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol. 1996;53:1270–5.Google Scholar
  209. 209.
    Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84:935–86.Google Scholar
  210. 210.
    Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99:749.Google Scholar
  211. 211.
    Alhasso A, Glazener CMA, Pickard R, et al. Adrenergic drugs for urinary incontinence in adults (Review). Cochrane Database for Systematic Reviews. 2005;3:art. No. CD001842.Google Scholar
  212. 212.
    Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual- serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40:161.Google Scholar
  213. 213.
    Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007;61:1349–55.Google Scholar
  214. 214.
    Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol. 2006;125:120–8.Google Scholar
  215. 215.
    Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:961–4.Google Scholar
  216. 216.
    Bump RC, Voss S, Beardsworth A, et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int. 2008;102:214–8.Google Scholar
  217. 217.
    Kaneko K, Fujinaga S, Ohtomo Y, et al. Combined pharmacotherapy for nocturnal enuresis. Pediatr Nephrol. 2001;16:662–4.Google Scholar
  218. 218.
    Natalin R, Reis LO, Alpendre C, et al. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2010;28:79–85.Google Scholar
  219. 219.
    Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35:827–38.Google Scholar
  220. 220.
    Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116:612–22.Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Karl-Erik Andersson
    • 5
    Email author
  • Helmut Madersbacher
    • 4
  • Waleed Altaweel
    • 3
  • Pawan Vasudeva
    • 2
  • Yasuhiko Igawa
    • 1
  1. 1.Department of Continence MedicineThe University of Tokyo Graduate School of MedicineTokyoJapan
  2. 2.VM Medical College, Safdarjang HospitalDelhiIndia
  3. 3.Department of UrologyKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
  4. 4.Department of UrologyUniversity HospitalInnsbruckAustria
  5. 5.Department of Clinical MedicineUniversity of AarhusAarhusDenmark

Personalised recommendations